Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up
- First Online:
- Cite this article as:
- Wu, L., Fernando Arevalo, J., Maia, M. et al. Jpn J Ophthalmol (2009) 53: 125. doi:10.1007/s10384-008-0622-y
- 79 Downloads
To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months.
This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg).
The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by ≥3 lines, and four (16%) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896).
There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.